NFKB1 and colitis: A recent study found that butyrolactone‐I reduces the production of IL‐1, IL‐6, and TNFα by inhibiting the TLR4/NF‐κB and mitogen‐activated protein kinases (MAPK) signaling pathways and reduces the inflammatory response of dextran sulfate sodium‐induced colitis in mice.241